Paul Hastings LLP represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $63.25…
Viking Therapeutics, Inc.’s $63.25 Million Initial Public Offering
